Takeda Pharmaceutical Co Ltd
TSE:4502
Takeda Pharmaceutical Co Ltd
TSE:4502
Price:
4 213
JPY
0.29%
Market Closed
Market Cap:
6.7T
JPY
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Takeda Pharmaceutical Co Ltd
4213
+12 (+0.29%)
| 52 Week Range |
3 903
4 482
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Takeda Pharmaceutical Co Ltd
Balance Sheet
Balance Sheet Decomposition
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
| Current Assets | 3.1T |
| Cash & Short-Term Investments | 857.7B |
| Receivables | 772.4B |
| Other Current Assets | 1.5T |
| Non-Current Assets | 13.1T |
| Long-Term Investments | 447.2B |
| PP&E | 2.1T |
| Intangibles | 10.1T |
| Other Non-Current Assets | 487.7B |
| Current Liabilities | 2.5T |
| Accounts Payable | 468.9B |
| Other Current Liabilities | 2T |
| Non-Current Liabilities | 6T |
| Long-Term Debt | 5T |
| Other Non-Current Liabilities | 921.8B |
Balance Sheet
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Currency: JPY
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
461 007
|
437 916
|
278 488
|
243 324
|
462 890
|
188 640
|
335 027
|
389 058
|
229 557
|
457 800
|
|
| Cash Equivalents |
461 007
|
437 916
|
278 488
|
243 324
|
462 890
|
188 640
|
335 027
|
389 058
|
229 557
|
457 800
|
|
| Short-Term Investments |
252 416
|
122 110
|
97 650
|
131 862
|
262 929
|
464 796
|
667 793
|
485 942
|
324 147
|
267 700
|
|
| Total Receivables |
466 829
|
430 571
|
444 778
|
428 792
|
749 119
|
784 921
|
812 714
|
724 377
|
681 693
|
697 610
|
|
| Accounts Receivables |
400 846
|
376 490
|
356 453
|
360 833
|
657 681
|
670 708
|
707 487
|
617 517
|
575 430
|
612 439
|
|
| Other Receivables |
65 983
|
54 081
|
88 325
|
67 959
|
91 438
|
114 213
|
105 227
|
106 860
|
106 263
|
85 171
|
|
| Inventory |
262 354
|
254 010
|
226 048
|
212 944
|
919 670
|
759 599
|
753 881
|
853 167
|
986 457
|
1 209 869
|
|
| Other Current Assets |
77 466
|
129 180
|
213 452
|
61 886
|
598 429
|
271 476
|
143 478
|
141 098
|
176 102
|
178 212
|
|
| Total Current Assets |
1 520 072
|
1 373 787
|
1 260 416
|
1 078 808
|
2 993 037
|
2 469 432
|
2 712 893
|
2 593 642
|
2 397 956
|
2 558 580
|
|
| PP&E Net |
526 162
|
551 916
|
527 344
|
536 801
|
1 331 931
|
1 386 370
|
1 453 917
|
1 582 800
|
1 691 229
|
1 989 777
|
|
| PP&E Gross |
526 162
|
551 916
|
527 344
|
536 801
|
1 331 931
|
1 386 370
|
1 453 917
|
1 582 800
|
1 691 229
|
1 989 777
|
|
| Accumulated Depreciation |
625 430
|
671 923
|
607 089
|
654 597
|
639 591
|
697 754
|
737 818
|
870 208
|
1 007 754
|
1 220 701
|
|
| Intangible Assets |
939 381
|
743 128
|
1 063 037
|
1 014 264
|
4 751 169
|
4 171 361
|
3 909 106
|
3 818 544
|
4 269 657
|
4 274 682
|
|
| Goodwill |
821 911
|
779 316
|
1 019 574
|
1 029 248
|
4 240 251
|
4 012 528
|
4 033 917
|
4 407 749
|
4 790 723
|
5 410 067
|
|
| Long-Term Investments |
281 966
|
186 190
|
303 047
|
304 385
|
299 922
|
369 455
|
348 350
|
330 133
|
378 857
|
430 608
|
|
| Other Long-Term Assets |
206 700
|
189 748
|
173 376
|
142 957
|
176 463
|
411 948
|
454 110
|
445 150
|
429 328
|
445 078
|
|
| Other Assets |
821 911
|
779 316
|
1 019 574
|
1 029 248
|
4 240 251
|
4 012 528
|
4 033 917
|
4 407 749
|
4 790 723
|
5 410 067
|
|
| Total Assets |
4 296 192
N/A
|
3 824 085
-11%
|
4 346 794
+14%
|
4 106 463
-6%
|
13 792 773
+236%
|
12 821 094
-7%
|
12 912 293
+1%
|
13 178 018
+2%
|
13 957 750
+6%
|
15 108 792
+8%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
124 365
|
135 205
|
125 713
|
133 705
|
212 348
|
211 627
|
232 105
|
295 933
|
307 453
|
319 955
|
|
| Short-Term Debt |
0
|
0
|
405 054
|
18
|
500 002
|
5 014
|
69
|
285
|
256
|
251
|
|
| Current Portion of Long-Term Debt |
154 178
|
228 464
|
139 974
|
0
|
484 944
|
581 803
|
22 084
|
203 708
|
339 344
|
367 000
|
|
| Other Current Liabilities |
792 494
|
493 544
|
695 605
|
603 786
|
1 355 755
|
1 377 454
|
1 518 918
|
1 645 804
|
1 834 887
|
1 625 897
|
|
| Total Current Liabilities |
1 016 824
|
857 213
|
1 366 346
|
737 509
|
2 553 049
|
2 175 898
|
1 773 176
|
2 145 730
|
2 481 940
|
2 313 103
|
|
| Long-Term Debt |
629 416
|
539 760
|
599 862
|
985 644
|
4 766 005
|
4 506 487
|
4 613 218
|
4 141 418
|
4 042 741
|
4 476 501
|
|
| Deferred Income Tax |
156 132
|
123 469
|
153 396
|
90 725
|
783 356
|
765 079
|
576 542
|
473 145
|
295 178
|
118 158
|
|
| Minority Interest |
69 129
|
62 511
|
54 704
|
19 985
|
4 006
|
4 003
|
4 140
|
504
|
549
|
741
|
|
| Other Liabilities |
287 644
|
292 440
|
278 225
|
275 176
|
504 372
|
646 144
|
772 180
|
734 202
|
783 219
|
927 025
|
|
| Total Liabilities |
2 159 145
N/A
|
1 875 393
-13%
|
2 452 533
+31%
|
2 109 039
-14%
|
8 610 788
+308%
|
8 097 611
-6%
|
7 739 256
-4%
|
7 494 999
-3%
|
7 603 627
+1%
|
7 835 528
+3%
|
|
| Equity | |||||||||||
| Common Stock |
64 044
|
64 766
|
65 203
|
77 914
|
1 643 585
|
1 668 123
|
1 668 145
|
1 676 263
|
1 676 345
|
1 676 596
|
|
| Retained Earnings |
1 601 326
|
1 523 127
|
1 511 817
|
1 557 307
|
1 595 431
|
1 369 972
|
1 509 906
|
1 479 716
|
1 541 146
|
1 391 203
|
|
| Additional Paid In Capital |
59 575
|
68 829
|
74 972
|
90 740
|
1 650 232
|
1 680 287
|
1 688 424
|
1 708 873
|
1 728 830
|
1 747 414
|
|
| Unrealized Security Profit/Loss |
60 771
|
0
|
67 980
|
73 037
|
46 380
|
22 891
|
41 983
|
22 068
|
12 470
|
15 729
|
|
| Treasury Stock |
18 203
|
0
|
48 734
|
74 373
|
57 142
|
87 463
|
59 552
|
116 007
|
100 317
|
51 259
|
|
| Other Equity |
354 620
|
269 421
|
223 023
|
272 799
|
303 499
|
69 673
|
324 131
|
912 106
|
1 495 649
|
2 493 581
|
|
| Total Equity |
2 137 047
N/A
|
1 948 692
-9%
|
1 894 261
-3%
|
1 997 424
+5%
|
5 181 985
+159%
|
4 723 483
-9%
|
5 173 037
+10%
|
5 683 019
+10%
|
6 354 123
+12%
|
7 273 264
+14%
|
|
| Total Liabilities & Equity |
4 296 192
N/A
|
3 824 085
-11%
|
4 346 794
+14%
|
4 106 463
-6%
|
13 792 773
+236%
|
12 821 094
-7%
|
12 912 293
+1%
|
13 178 018
+2%
|
13 957 750
+6%
|
15 108 792
+8%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
786
|
784
|
781
|
781
|
1 555
|
1 558
|
1 563
|
1 550
|
1 555
|
1 569
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
